Ligand ID: RXM Drugbank ID: DB01220(Rifaximin) Indication:Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE B 927PHE B1052VAL B 785PHE B 797VAL B1065 | 1.57A | 18.62 | None | ||
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE A 927PHE A1052VAL A 785PHE A 797VAL A1065 | 1.58A | 19.04 | None | ||
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE B 927PHE B1052VAL B 785PHE B 797VAL B1065 | 1.60A | 18.90 | None |